# Ezetrol Post-Marketing Study

> **NCT00753883** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 40 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** simvastatin
- **DRUG:** Ezetimibe

## Key facts

- **NCT ID:** NCT00753883
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-05
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2008-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00753883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00753883, "Ezetrol Post-Marketing Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00753883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*